Ayisha Sharma

Roche on Wednesday morning said it has “minor exposure” from the Biosecure Act, adding that it is making strides in China's pharma and diagnostics markets.

AstraZeneca CEO Pascal Soriot vigorously defended his recently secured $23.5 million pay package, citing the UK pharma's need to compete for talent.

AstraZeneca put the spotlight on its near-20% revenue growth during first-quarter earnings, driven in part by its success in emerging markets.

Plus, news about Biodexa Pharmaceuticals: RevOpsis Therapeutics secures $16.5M seed round: The San Carlos, CA-based biotech will use the

Enhertu notched another win for AstraZeneca and Daiichi Sankyo that could see uptake moved slightly earlier in a specific subset of breast cancer patients.

Novartis is looking to build on its radiopharma research machinery.

GSK's vaccines portfolio is front and center as it kicks off 2024.

GSK wants to present Blenrep to regulatory bodies sooner. The UK pharma will submit Blenrep in second-line multiple myeloma to US, European

Novo Nordisk is still hitting a glass ceiling in revenues due to GLP-1 supply constraints even as sales keep rising.

Novo Nordisk's GLP-1 drugs may have been the center of attention during its first-quarter earnings call, but the company's broader diabetes portfolio beat its target for a greater global market stake one year early.